7 days in healthcare (January 23rd-29th, 2023)

 

Summary

From the point of view of Biomedicine, it is worth highlighting, as the Nature article does, that among the 7 most promising technologies for 2023, at least three are directly related to biomedicine. It seems that not only neurons have a role in brain function, but also a relevant role of glial cells in certain disorders is beginning to be recognized.

As regards Global Health, the WHO requests 2.5 billion dollars to deal with health emergencies, particularly in Yemen, Afghanistan, Syria and Ethiopia.

As for International Health Policy, a consensus began to be created three years after the start of the pandemic that, although not totally overcome, it is no longer the emergency that it was. The problems in China with the covid continue. The crisis in the NHS is the biggest for many years. Basically, there are two positions: the one that seems to be held by the current conservative government that the system is unsustainable without co-payments and very profound changes; or the one represented by The Lancet, which says that the system is perfectly viable, if it is provided with more resources. What is clear is that the UK lags behind other European countries in many resources (hospital beds etc.). Two good news in terms of health policy are led by countries that are not usually at the forefront on these issues: the smoking ban in Mexico and the mental health law in Nigeria. Tensions between governments and pharmaceutical companies over the price of medicines are increasing and this time they are not only in Europe, but also in the United States (the largest pharmaceutical market).

If we talk about National Health Policy (Spain), the incidence of covid continues to drop, although mortality remains high (above 250 deaths per week). The medical conflict in public health continues, mainly in Primary Care. While there are communities that have reached agreements (Andalusia, Navarra, Aragon, Extremadura), in others (Madrid, Catalonia) there does not seem to be any sign of agreement, which makes us think and we will have to draw conclusions about different behaviors of the Administrations and of medical leaders. Conflict also between private health doctors and health insurers. It seems that the Equity Law is going ahead, after Darias’ agreement with Podemos. Interesting agreement in Madrid so that hospital specialists can also take leave. Aragon proposes that the issue of health be dealt with in the President’s Conference, which seems reasonable, given the seriousness of the problems, although the document of said community does not contain great innovative elements. After the more than debatable success of the operations in Alzira and Torrevieja, it seems that the Valencian government also wants to rescue Denia. At this point, a deeper and more articulate justification of political decisions should be demanded.

In the field of Companies, at the international level, it is necessary to highlight the great activity of private equity companies worldwide in the field of health, as revealed by the Bain report. In Spain, Ribera Salud leaves Extremadura. Important investments in our country from Bayer and Novartis are confirmed

Biomedicine

Global Health

International Health Policy

National health policy

Companies